Glioblastoma Multiforme Market Report: Trends, Forecast and Competitive Analysis to 2030

Glioblastoma Multiforme Market Report: Trends, Forecast and Competitive Analysis to 2030

Glioblastoma Multiforme Trends and Forecast

The future of the global glioblastoma multiforme market looks promising with opportunities in the hospitals, clinics, and ambulatory surgical centers markets. The global glioblastoma multiforme market is expected to reach an estimated $1.2 billion by 2030 with a CAGR of 8.2% from 2024 to 2030. The major drivers for this market are rising R&D costs, expanding glioblastoma multiforme prevalence, and advantageous regulatory environments, as well as, growing prevalence of brain cancers and having a robust product pipeline.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Glioblastoma Multiforme by Segment

The study includes a forecast for the global glioblastoma multiforme by treatment, drug, end use, and region.

Glioblastoma Multiforme Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Tumor Treating Field Therapy
• Immunotherapy

Glioblastoma Multiforme Market by Drug [Shipment Analysis by Value from 2018 to 2030]:

• Temozolomide
• Bevacizumab
• Lomustine
• Carmustine Wafers
• Others

Glioblastoma Multiforme Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Clinics
• Ambulatory Surgical Centers

Glioblastoma Multiforme Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Glioblastoma Multiforme Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies glioblastoma multiforme companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the glioblastoma multiforme companies profiled in this report include-

• Merck & Co
• Amgen
• F. Hoffmann-La Roche
• Pfizer
• Teva Pharmaceutical Industries
• Sun Pharmaceutical Industries
• Pharmaceuticals
• Amneal Pharmaceuticals
• Karyopharm Therapeutics
• Sumitomo Dainippon Pharma Oncology

Glioblastoma Multiforme Market Insights

Lucintel forecasts that radiation therapy will remain the largest segment over the forecast period because it is efficient and strongly endorsed for recurring cases of brain tumors, as well as, advancements in radiation technology and increased survival rates.

North America will remain the largest region over the forecast period due to government backing for healthcare sector advancement, widespread awareness regarding rare disorders, convenient access to high-quality medical institutions, and favorable reimbursement policies in this region.

Features of the Global Glioblastoma Multiforme Market

Market Size Estimates: Glioblastoma multiforme market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Glioblastoma multiforme market size by treatment, drug, end use, and region in terms of value ($B).

Regional Analysis: Glioblastoma multiforme market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different treatment, drug, end use, and regions for the glioblastoma multiforme market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the glioblastoma multiforme market.

Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the glioblastoma multiforme market size?

Answer: The global glioblastoma multiforme market is expected to reach an estimated $1.2 billion by 2030.

Q2. What is the growth forecast for glioblastoma multiforme market?

Answer: The global glioblastoma multiforme market is expected to grow with a CAGR of 8.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the glioblastoma multiforme market?

Answer: The major drivers for this market are rising R&D costs, expanding glioblastoma multiforme prevalence, and advantageous regulatory environments, as well as, growing prevalence of brain cancers and having a robust product pipeline.

Q4. What are the major segments for glioblastoma multiforme market?

Answer: The future of the global glioblastoma multiforme market looks promising with opportunities in the hospitals, clinics, and ambulatory surgical centers markets.

Q5. Who are the key glioblastoma multiforme market companies?

Answer: Some of the key glioblastoma multiforme companies are as follows:

• Merck & Co
• Amgen
• F. Hoffmann-La Roche
• Pfizer
• Teva Pharmaceutical Industries
• Sun Pharmaceutical Industries
• Pharmaceuticals
• Amneal Pharmaceuticals
• Karyopharm Therapeutics
• Sumitomo Dainippon Pharma Oncology

Q6. Which glioblastoma multiforme market segment will be the largest in future?

Answer: Lucintel forecasts that radiation therapy will remain the largest segment over the forecast period because it is efficient and strongly endorsed for recurring cases of brain tumors, as well as, advancements in radiation technology and increased survival rates.

Q7. In glioblastoma multiforme market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to government backing for healthcare sector advancement, widespread awareness regarding rare disorders, convenient access to high-quality medical institutions, and favorable reimbursement policies in this region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the glioblastoma multiforme market by treatment (surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating field therapy, and immunotherapy), drug (temozolomide, bevacizumab, lomustine, carmustine wafers, and others), end use (hospitals, clinics, and ambulatory surgical centers), and region (North America, Europe, Asia Pacific, and the Rest of the World)?

Q.2. Which segments will grow at a faster pace and why?

Q.3. Which region will grow at a faster pace and why?

Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?

Q.5. What are the business risks and competitive threats in this market?

Q.6. What are the emerging trends in this market and the reasons behind them?

Q.7. What are some of the changing demands of customers in the market?

Q.8. What are the new developments in the market? Which companies are leading these developments?

Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?

Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?

Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Please note: It will take 2-3 business days to deliver the report upon receipt the order.